Effect of MF-268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex.

CUADRA, G., ZHU, X-D., MAGGI, A., BRUFANI, M., PAGELLA, P.M., WILLIAMS, E. AND GIACOBINI, E.

JOURNAL OF NEUROSCIENCE RESEARCH

Wiley-Liss, Inc.

Lugar: United States; Año: 1996 vol. 43 p. 120 - 120

0360-4012

span lang="en" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: PT-BR; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: ES-MX; mso-bidi-language: AR-SA">MF-268 bitartrate [(3a S, 8a R)-1,2,3,3a,8,8a-hexahy-dro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol[8-(cis2,-6-dimethyl-morpholin-4-yl)octyl]-carbamate L-bitar-trate hydrate; Mediolanum Farmaceutici, Milan, Italy] is a pseudo-reversible carbamate-type cholinest-erase inhibitor (ChEI) which interacts with the catalytic and regulatory anionic site of the enzyme. Its effects on extracellular levels of acetylcholine (ACh), norepinephrine (NE), dopamine (DA), and serotonin (5-HT, 5-hydroxytryptamine) were stu